Company Overview of Hoffmann-La Roche Inc.
Hoffmann-La Roche Inc., also known as Roche, operates as a research-focused healthcare company that discovers and develops diagnostic and therapeutic products for patients and healthcare professionals. The company offers drugs for various diseases, including cancer, viral infections, metabolic, central nervous system disorders, and inflammatory diseases, as well as pharmaceutical products for bioOncology, immunology and ophthalmology, metabolism and primary care, and virology and specialty care; and medical diagnostic products, such as diabetes care products, blood coagulation monitoring products, hospital and laboratory systems, research products, and point of care diagnostics portal. It al...
340 Kingsland Street
Nutley, NJ 07110
Founded in 1905
Key Executives for Hoffmann-La Roche Inc.
Chief Executive Officer and President
Senior Principal Scientist of Respiratory Inflammation and Autoimmune Diseases
Global Head of Roche Pharma Partnering
Head of Roche Pharmaceuticals Western Europe Region
Business Development Director
Compensation as of Fiscal Year 2014.
Hoffmann-La Roche Inc. Key Developments
Hoffmann-La Roche Inc. Presents at Boston Biotech Conferences LLC's The New York CEO Conference, Nov-13-2013 01:20 PM
Sep 25 13
Hoffmann-La Roche Inc. Presents at Boston Biotech Conferences LLC's The New York CEO Conference, Nov-13-2013 01:20 PM. Venue: Apella, 450 East 29th Street, New York, NY 10016, United States. Speakers: Bob Silverman.
Intas Pharma Signs Settlement and License Agreement with Roche for Xeloda
Jun 28 13
Intas Pharmaceuticals and its subsidiary Accord Healthcare Inc. announced that it has entered into a settlement and license agreement with Hoffmann-La Roche Inc. that will resolve pending patent litigation related to Xeloda Tablets, 150 mg and 500 mg, known generically as Capecitabine Tablets. This product is an orally administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Xeloda Tablets had U.S. sales of approximately $706.2 million for the 12 months ending Dec. 31, 2012, according to IMS Health. Intas reported that Hoffmann-La Roche Inc. had filed patent infringement suit against Accord Healthcare and Intas Pharmaceuticals following Accord's submission to the U.S. Food and Drug Administration of an Abbreviated New Drug Application (ANDA) for a generic version of Xeloda Tablets. As part of the agreement, the Company said that Hoffman La Roche Inc. has granted Accord a license to enter the U.S. market with a generic version of Xeloda Tablets ahead of its exclusivity period. Pursuant to the agreement, pending litigation would be dismissed. All other terms and conditions of the settlement are confidential, and the agreement itself is subject to review by the U.S. Department of Justice and the Federal Trade Commission.
Hoffmann-La Roche Inc. Presents at Windhover's Therapeutic Area Partnerships Conference, Nov-29-2012 02:00 PM
Nov 27 12
Hoffmann-La Roche Inc. Presents at Windhover's Therapeutic Area Partnerships Conference, Nov-29-2012 02:00 PM. Venue: Westin Copley Place, Boston, Massachusetts, United States. Speakers: Kevin P. Anderson, PhD, Global Head, Virology Partnering.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|